| Status: Supported for use via the One Wales Medicines process | |
Using the agreed starting and stopping criteria infliximab can be made available within NHS Wales for the treatment of moderate to severe hidradenitis suppurativa where licensed and health technology appraisal approved treatments are unsuitable. The choice of infliximab product prescribed should be based on the acquisition cost and in accordance with the One Wales advice on use of biosimilars. The risks and benefits of the off-label use of infliximab for this indication should be clearly stated and discussed with the patient to allow informed consent. Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed. This recommendation has been endorsed by the All Wales Medicines Strategy Group (AWMSG) and ratified by Welsh Government. This advice will be reviewed after 12 months or earlier if new evidence becomes available. |
Darllen yn Gymraeg / Read in English
Beth benderfynodd Grŵp Asesu Meddyginiaethau Cymru’n Un?
Gellir rhoi infliximab i drin hidradenitis suppurativa, a elwir hefyd yn HS – cyflwr croen poenus a hirdymor sy'n achosi crawniadau a chreithiau ar y croen. Dim ond i drin HS cymedrol neu ddifrifol y gellir rhoi Infliximab, a hynny pan nad yw triniaethau eraill wedi bod yn effeithiol neu pan nad ydynt yn addas.
Bydd infliximab ar gael i gleifion cymwys sydd wedi cofrestru gyda phractis meddyg teulu yng Nghymru, hyd yn oed os oes angen iddynt dderbyn eu triniaeth y tu allan i Gymru.
Nid yw infliximab wedi'i drwyddedu ar gyfer trin HS, felly gelwir ei ddefnyddio i drin HS yn ddefnydd "oddi ar y label". Pan gaiff meddyginiaeth ei defnyddio yn “all-drwydded”, rhaid i'ch meddyg esbonio'n glir i chi y risgiau a'r manteision o gymryd y feddyginiaeth. Dylai eich meddyg roi gwybodaeth glir i chi, siarad â chi am eich opsiynau a gwrando'n ofalus ar eich barn a'ch pryderon. Darllenwch ein taflen wybodaeth i gleifion am ddefnydd di-drwydded ac all-drwydded o feddyginiaethau.
Mae Grŵp Asesu Meddyginiaethau Cymru'n Un ac AWTTC yn adolygu'r penderfyniad hwn yn rheolaidd i weld a oes unrhyw dystiolaeth newydd a allai effeithio ar y penderfyniad hwn.
Am ragor o wybodaeth am HS, ewch i: Living Life with HS (Saesneg yn unig)
What did the One Wales Medicines Assessment Group decide?
Infliximab can be given to treat hidradenitis suppurativa, also known as HS, a painful long-term skin condition that causes skin abscesses and scarring on the skin. Infliximab can only be given to treat moderate or severe HS when other treatments have not worked or are not suitable.
Infliximab will be available to eligible patients who are registered with a GP practice in Wales, even if they need to receive their treatment outside Wales.
Infliximab is not licensed to treat HS, so using it to treat HS is called “off label”. When a medicine is used “off-label”, your doctor must clearly explain to you the risks and benefits of taking the medicine. Your doctor should give you clear information, talk with you about your options and listen carefully to your views and concerns. Read our patient information leaflet about unlicensed and off-label use of medicines.
The One Wales Medicines Assessment Group and AWTTC review this decision regularly to see if there is any new evidence that may affect this decision.
For more information on HS visit Living Life with HS
Starting criteria
Infliximab is an option for patients with moderate-to-severe (International Hidradenitis Suppurativa Severity Score [IHS4] ≥ 4) hidradenitis suppurativa following failure of, or intolerance to, biologic treatments adalimumab and secukinumab.
IHS4 is calculated by the number of nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4)2.
Screening
Prior to commencing treatment with a biologic medicine, pre-screening should be undertaken to exclude:
This list is not exhaustive refer to local guidelines and Summary of Product Characteristics (SmPC)3.
Dose
The recommended treatment dose regimen for infliximab is 5 mg/kg by intravenous infusion on weeks 0, 2 and 6 followed by 5 mg/kg every 8 weeks.
The maintenance dose frequency may be increased to every 4 weeks if response is sub-optimal.
The infliximab product available at the lowest acquisition cost should be prescribed.
Outcome data
The following should be collected to inform future reviews of this One Wales decision:
Monitoring
Prescribers should advise patients of rare incidences of polyarthritis associated with infliximab treatment for HS4,5.
Prescribers should consult the relevant Summary of Product Characteristics for any additional monitoring requirements and potential adverse effects3.
Stopping criteria
For patients who develop hepatotoxicity during treatment (jaundice and/or alanine aminotransferase [ALT] increases at or above 5 times the upper limit of normal), treatment should be discontinued3.
References
Medicine: infliximab
Indication: treatment of moderate to severe hidradenitis suppurativa that does not respond to licensed treatments or when licensed treatments are not suitable
Meeting date: 5 October 2026
| Criterion: Clinical effectiveness and safety |
|
OWMAG opinion The group noted the two biologic treatments (adalimumab and secukinumab) currently available for patients with moderate-to-severe hidradenitis suppurativa and the relatively short duration of effective disease control. The group acknowledged the proposed place in therapy for infliximab as an option for patients who have not responded, or who have relapsed following these treatments. It was recognised that should other biologic treatments, such as bimekizumab and upadacitinib, be licensed and approved by NICE or AWMSG in the future, infliximab would still be a relevant option after these treatments have been tried. OWMAG considered the available clinical evidence, including the UK-based randomised control trial by Grant et al. (2010), systemic review and network meta-analysis by Shih et al. (2022) and two retrospective cohort studies by Le et al. (2026) and Srour et al. (2026). Studies were heterogenous with respect to previous treatments and outcome measures. Overall, the Group considered infliximab was likely to be an effective treatment option for patients with moderate-to-severe HS. The group noted the study by Srour et al (2026) where the maintenance dose of infliximab was increased to every 4 weeks. The group agreed that the results suggested that increased dosing could be considered effective and safe for patients who have a suboptimal response to maintenance every 8 weeks. The group noted that, in general, adverse events reported for infliximab in the treatment of HS were in accordance with those in the SmPC. However, there are reports by Acquacalda et al. (2015) and Van Rappard et al. (2011) of 8 cases of polyarthritis in patients with HS following treatment with infliximab. The clinical expert also noted that inflammatory arthritis is more common in people with HS. OWMAG agreed it would be prudent to advise patients of this rare adverse event. OWMAG considers that, while direct clinical evidence for infliximab in HS is limited, the available data suggest potential clinical benefit for patients who do not respond to, have lost response, or are unsuitable for treatment, with licensed and available treatments. OWMAG considers that the evidence for an increase in dosing frequency suggests benefit for patients with suboptimal response to standard dosing.
|
| Criterion: Cost-effectiveness |
|
OWMAG opinion
There is no published cost-effectiveness evidence available for this treatment. AWTTC did not conduct cost effectiveness analysis as the available clinical evidence was not considered suitable to support a reasonable cost effectiveness model and infliximab treatment was considered to be either cost saving or low when compared to alternative treatment options. |
| Criterion: Budget impact |
|
OWMAG opinion
OWMAG considers the clinical estimate of patient numbers to be reasonable. The estimate was based on the experience of a clinician who treated a large population of people with HS in Wales. It is possible that as more treatments for HS become available this number may fall. The group considers bimekizumab, upadacitinib and best supportive care (BSC) to be reasonable comparator treatments. The main driver of the budget impact is the cost of the comparator, bimekizumab. OWMAG acknowledge that if bimekizumab becomes routinely available cost savings associated with infliximab will be lower. OWMAG note the limitations and uncertainties highlighted in the budget impact. In particular the likely underestimation for BSC costs and uncertainties around the duration of treatment and lack of adverse event costs. Costs such as surgery, drainage of boils, attendance at A&E and visits to healthcare providers are not included, the group recognise that offset costs are likely to be considerably higher than estimated. The group noted the modest reduction in cost savings if infliximab dosing frequency was increased for patients who have suboptimal response at 6 months. OWMAG considers that, based on the estimated number of eligible patients and the expected treatment pathway, the overall budget impact is likely to be either cost saving or low. The use of infliximab is expected to reduce NHS resource use for patients who respond to treatment. OWMAG consider the budget impact to be reasonable value for money for NHS Wales. |
| Criterion: Resource use |
|
OWMAG opinion
OWMAG note that treatment with infliximab involves intra-venous infusion at an outpatient department. Comparator treatments may be self-administered (bimekizumab after three outpatient appointments). Upadacitinib is an oral treatment. The group accept that monitoring requirements are likely to be the same for infliximab and active comparator treatments. The group considers that any potential additional resource use with infliximab is acceptable, as it may be offset by reduced management needs associated with uncontrolled disease/HS flare. |
| Criterion: Other factors |
|
OWMAG opinion
OWMAG considered the contribution by the patient representative, in particular acknowledging the first-hand account of living with HS. Providing an account of the numerous surgical procedures that patients may have to endure. The risk of progressive irreversible scarring was noted by the clinical expert and having a window of opportunity to prevent such scarring. The Group understand the burden of disease on the quality of life for patients and their carers. In particular the chronic pain and impact on further education, work, mental health, family and relationships. The clinical expert noted that for people who are failing current treatments there is a reliance on repeated use of antibiotics was in conflict with the principles of antibiotic stewardship. OWMAG acknowledge that current treatment options often have a short-lived duration of efficacy and patients would welcome additional treatment options for when all licensed and HTA-approved treatments have been exhausted. |
| Final recommendation |
|
OWMAG recommends the use of infliximab for the treatment moderate-to-severe hidradenitis suppurativa where licensed and health technology appraisal approved treatments are unsuitable. OWMAG recommends an increase in dose frequency to every four weeks for patients with sub-optimal response after six months standard treatment. This recommendation is subject to the development of appropriate start/stop criteria. |
| Summary of rationale |
|
Despite limited clinical evidence, OWMAG are of the opinion that infliximab may provide meaningful clinical benefit in selected patients with moderate-to-severe HS where licensed and health technology appraisal approved treatments are unsuitable, sufficiently to consider the associated cost to be a reasonable use of NHS resources. Real-world data will be captured to further assess the benefit of this treatment in this patient cohort. |
Licence status: Infliximab is not licensed for treating hidradenitis suppurativa (HS); its use for this indication is off label.
Guidelines: Infliximab is recommended for the treatment of HS in guidelines published by the British Association of Dermatologists and European Hidradenitis Suppurativa Foundation.
Clinical evidence: One randomised controlled trial compared intravenous infliximab 5 mg/kg (on Weeks 0, 2 and 6, and then every eight weeks) with placebo in moderate-to-severe HS. In sub-analyses, infliximab showed significant improvement in HS Severity Index (HSSI) compared with placebo.
Safety: Side effects are in line with the licensed use of infliximab, though studies have reported cases of polyarthritis during infliximab therapy for HS, which resolved after treatment was discontinued.
Patient factors: Questionnaires submitted to AWTTC by people with HS refer to extreme pain, toll on mental health, impact on relationships and restrictions to everyday activities. Patients welcome any new treatment which may reduce flares and in particular the pain associated with this condition.
Cost effectiveness: No cost-effectiveness evidence was identified for this use of infliximab, and no analyses of cost effectiveness have been done.
Budget impact: The addition of infliximab is estimated to decrease the spend associated with this patient group in Wales by [commercial in confidence text removed] in Year 1 and [commercial in confidence text removed] in Year 2 compared with current last line biologics accessed through individual patient funding requests. Compared to best supportive care alone, infliximab would increase the budget impact by [commercial in confidence text removed] in Year 1 and [commercial in confidence text removed] in Year 2. However, this excludes any additional saving due to infliximab treatment, including reduced hospital admissions and additional procedures. An estimated budget impact for an increase in dose frequency to every four weeks for patients with inadequate response has also been provided.
Impact on health and social care services: We would expect a minimal impact on health and social care services.
Innovation and/or advantages: Infliximab offers an additional much-needed treatment option for patients whose HS has stopped responding to standard therapies, and patients for whom standard therapies are not suitable.
Clinicians in Wales consider there is an unmet need for treating moderate-to-severe hidradenitis suppurativa (HS; acne inversa) that does not respond to licensed and National Institute for Health and Care Excellence (NICE)-recommended treatments (adalimumab and secukinumab), or for when licensed treatments are not suitable. They have identified a cohort of patients who could benefit from infliximab treatment and requested that it is considered for off-label use in this indication. This request is supported by the British Association of Dermatologists (BAD), as evidenced by the BAD Guidelines.
The AWMSG Scrutiny Panel agreed that infliximab was suitable for assessment though the One Wales medicines process.
The indication under consideration is the off-label treatment of moderate-to-severe HS that does not respond to licensed treatments, or when licensed treatments are not suitable.
Not applicable for this indication, off-label.
Infliximab is not licensed to treat moderate-to-severe HS that does not respond to licensed treatments or when licensed treatments are not suitable. [commercial in confidence text removed].
The proposed dose is 5 mg/kg by intravenous infusion over a 2-hour period at Week 01. This dose is the recommended infliximab dose to treat most of the indications for which it is licensed. A second, and third dose may be given, two and six weeks later, and then every eight weeks. Due to risk of acute infusion-related reactions, patients should be monitored during and for at least one to two hours post-infusion1. Clinicians have requested that an option for increased dose frequency to every four weeks is considered for patients who have inadequate response after six months of treatment.
Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin2. The exact cause of HS is unknown2. Unlike a simple skin infection, HS is a complex condition that can form deep, painful lumps, nodules, and abscesses in skin-fold areas – most commonly the armpits, groin, buttocks, inner thighs, and under the breasts, although HS can occur anywhere on the body3. Over time, these recurring episodes can form sinus tracts – persistent, draining tunnels under the skin3.
The severity of HS is usually assessed using the Hurley staging system4. Patients with moderate HS (Hurley stage II) have recurrent lesions separated by normal skin with sinus tract formation and scarring. In severe HS (Hurley stage III) patients have multiple lesions coalescing into inflammatory plaques involving most of the affected area4.
In the UK, two biologic therapies are approved by NICE to treat moderate to severe HS: adalimumab and secukinumab5,6. However, clinicians in Wales report that the effects of these biologics generally only last for one or two years7,8, while HS can persist for many years.
The prevalence of HS is approximately 1% of the UK population9. It can affect anyone but is more common in women and in people with darker skin9.
Clinicians in Wales estimate that about 40% of patients have moderate-to-severe (Hurley stage II to III) disease. Based on Secure Anonymised Information Linkage (SAIL) Databank figures, clinicians estimate that each year in Wales, about 10 patients with HS would be eligible for treatment with infliximab.
No licensed alternative treatments are routinely available for patients who have not responded to licensed and health technology assessment (HTA) approved treatments; bimekizumab (licensed for HS) or upadacitinib (currently off- label [commercial in confidence text removed]) are being considered for HTA and can only be requested through an individual patient funding request (IPFR). NICE terminated an appraisal of bimekizumab due to non-submission by the company10, but the company are planning to submit for appraisal by the All Wales Medicines Strategy Group (AWMSG; date of advice to be determined). Upadacitinib has been topic selected by NICE and guidance is awaiting development11. Povorcitinib is undergoing appraisal with NICE for treatment of moderate to severe HS where a tumour necrosis factor (TNF)-alpha inhibitor is not suitable, did not work or has stopped working12. Infliximab is a TNF-alpha inhibitor therefore the patient cohort under consideration is different from that being considered for povorcitinib.
The British Association of Dermatologists (BAD) guideline for the treatment of HS, published in 2019, recommends initial treatment with topical clindamycin and oral tetracycline antibiotics plus dressings for lesions and lifestyle advice4. For HS that does not respond to these treatments, oral treatments such as acitretin and dapsone are recommended. For HS that continues not to respond, the guideline recommends adalimumab treatment. Infliximab 5 mg/kg every eight weeks may be considered in people with moderate-to-severe HS that is unresponsive to adalimumab therapy4.
Since the publication of the BAD guideline, a second biologic, secukinumab, has been licensed and recommended by NICE for the treatment of moderate-to-severe HS if adalimumab is not suitable, did not work, or has stopped working6.
The European Hidradenitis Suppurativa Foundation’s updated 2025 guideline advises modifying therapy if there is no significant reduction in the inflammatory activity of the lesions or no improvement of the quality of life is observed after 12 weeks13. For moderate-to-severe HS the guideline recommends that intravenous infliximab may be considered as third-line treatment, after second-line treatment with licensed biologics (adalimumab, bimekizumab and secukinumab) has been unsatisfactory. The recommended dosage and duration of treatment are 5 mg/kg intravenous infliximab given at Weeks 0, 2 and 6, and then every eight weeks13.
The All Wales Therapeutics and Toxicology Centre (AWTTC) conducted a literature search during 27–29 July 2026, to look for evidence about the use of infliximab to treat moderate-to-severe HS.
Searches were conducted on 27 July 2026 in MEDLINE ALL (Ovid), Embase (Ovid) and the Cochrane Library from database inception to the most recent update available. Our search terms were: infliximab, renflexis, remicade, zessly, remsima, inflectra, flixabi; hidradenitis suppurativa; acne inversa. Pre-set search filters prepared by Canada’s Drug Agency were used to search MEDLINE and Embase for economic evaluations and quality-of-life information.
The primary outcomes of interest were: symptom improvement or resolution in randomised controlled trials (RCT), systematic reviews, network meta-analyses, guidelines, case series, retrospective studies, health-related quality of life, economic evaluations, adverse events. No date restrictions were applied; results were restricted to English language. Targeted searches of Google and Google Scholar were also performed. Conference abstracts, letters and editorials were excluded. Clinical authors at AWTTC sifted and screened the results of the searches for clinical evidence, economic evaluations and quality of life. No relevant economic evaluations were identified.
The clinical literature search identified a total of 956 records, from which 172 duplicates were removed. The remaining 784 records were screened by inspecting titles and abstracts, and the full texts of 64 papers were reviewed for eligibility. We focused on studies that recorded the dose of infliximab as the dose recommended for most licensed indications in the Summary of Product Characteristics (SmPC; 5 mg/kg on Weeks 0, 2 and 6, and then every eight weeks) and the BAD guideline (5 mg/kg every eight weeks)1,4. An increased frequency of dosing to 5 mg/kg every four weeks was also included. We have not included studies using higher doses of infliximab, studies that focused on surgery, non-RCT studies that were included in the Shih et al. systematic review, single case reports, older guidelines and older studies with less than 10 patients. We identified six studies to include in this report, including one clinical trial of infliximab to treat HS, one systematic review, three retrospective studies and one study with increased dose frequency. See the PRISMA diagram in Appendix 1.
Efficacy
Randomised controlled trial
Grant et al. (2010) conducted a randomised, double-blind, placebo-controlled crossover trial of infliximab therapy in patients with moderate to severe HS14. The study recruited 38 adults with moderate to severe HS and at least one of the following: HS lasting more than one year; more than five steroid injections per year; failed systemic retinoid treatment; failed antibiotic treatment; or patients with a history of reconstructive surgery. Moderate to severe HS was defined by a HS Severity Index (HSSI) score greater than 8. HSSI is a composite score ranging from 0–19 assessing: number of sites involved; percentage of body surface involved; number of lesions; number of dressing changes; pain quantified by visual analogue scale (VAS).
Thirty eight patients were randomised to receive infliximab (n = 15) at 5 mg/kg on Weeks 0, 2 and 6 and every eight weeks thereafter up to Week 22, or placebo (n = 23) on weeks 0, 2 and 6. Treatments were unblinded after Week 8 and patients in the placebo group could cross over to infliximab treatment. An observation phase followed from treatment end up to Week 5214.
The primary endpoint was change in HSSI score at Week 8 from baseline14. Secondary endpoints included: change in Dermatology Life Quality Index (DLQI), VAS and Physician Global Assessment (PGA) at Week 8 from baseline; improvement in disease severity in patients in the placebo group crossing over to infliximab at Week 8 before and after cross over; and change in disease severity at Week 22 (end of infliximab treatment) and at Week 52 (end of study)14.
The number of patients with ≥ 50% decrease from baseline in HSSI at Week 8 was higher in the infliximab group than in the placebo group, although the difference was not significant (p = 0.092)14. Post-hoc HSSI composite analysis of patients achieving between 25% and 50% decrease in HSSI from baseline showed a significant difference between groups (p < 0.001); 60% in the infliximab group (compared with 5.6% in the placebo group). Most patients treated with placebo (88.9%) had a < 25% decrease in HSSI from baseline compared with 13.3% of patients treated with infliximab. Infliximab showed significant improvements compared to placebo for DLQI, VAS and PGA14.
Systematic review
Shih et al. (2022) conducted a systematic review and meta-analysis that identified 19 studies published between 2003 and 2021 that reported outcomes of infliximab use in patients with HS (n = 341)15. Studies included one randomised control trial (Grant et al., 2010; summarised above), four open-label trials and 13 cohort studies: one prospective and 12 retrospective). Patients with HS severity data (n = 299) had moderate-to-severe HS. Previously failed treatments, where reported, were varied and infliximab was not necessarily placed after failure of another biologic treatment. The dose of infliximab was 5 mg/kg for 10 studies. Five studies used infliximab at 5 mg/kg to 10 mg/kg with a frequency of maintenance dose between four and eight weeks15.
The pooled response rate of HS to infliximab was 83% (95% confidence interval [CI]: 0.71 to 0.91) with 17 studies reporting a response rate > 50%15. There was significant heterogeneity between studies (I2 = 89%). The analysis concluded that overall, infliximab is an effective treatment for patients with moderate-to-severe HS15.
Retrospective study
Le et al. (2026) conducted a retrospective study of 55 patients with Hurley Stage II or III HS who were treated with infliximab at a centre in the USA during July 2015–October 2025, and who had at least one measurement of serum infliximab trough concentration16. Thirty-nine (71%) patients had previously been exposed to biologic (adalimumab) therapy. Nineteen patients (35%) responded to infliximab therapy, 36 (65%) had suboptimal responses (19 primary and 17 secondary suboptimal responses). Baseline demographics, comorbidities, smoking, and prior adalimumab exposure (39/55; 70.9%) were similar across the responder groups. Hurley stage III was more prevalent among suboptimal responders than responders, occurring in 100% of patients with primary non-response and 94.1% of those with secondary non-response, compared with 63.2% of responders (p = 0.002)16.
Anti-infliximab antibodies (ATIs) were detected exclusively among suboptimal responders, most often in secondary suboptimal responders (52.9%; p = 0.0001)16. The infliximab dose was escalated in nine patients with low infliximab trough concentrations and negative ATIs, with a subsequent clinical response observed in six patients. The mean duration of infliximab use was 8 months (range 4–19)16.
Increased dosing frequency
Clinicians have requested consideration of an increase in frequency of dose to 5 mg/kg every 4 weeks for patients with insufficient response. Three studies were identified that included increased dose and/or frequency of infliximab and had not been included in the systematic review by Shih et al. (2022). In two studies the dose of infliximab had been increased to between 7.5 mg/kg 12.5 mg/kg and so will not be discussed further. A study by Srour et al. (2026) report on a retrospective cohort study of 40 HS patients treated in a single centre in Israel. All patients had Hurley Stage II or III HS and were treated with infliximab 5 mg/kg every four weeks following failure of adalimumab. Outcomes measured were HS clinical response (HiSCR) 50 (a ≥ 50% decrease in the number of abscesses and inflammatory nodules without an increase in abscesses or draining fistulas) and DLQI. HiSCR 50 was achieved in 29 patients (72.5%) at 24 weeks, response was maintained at 48 weeks in 26 patients (65%). A sustained response after 48 weeks of treatment was reported in in 86.2% of the 29 initial responders. Mean DLQI was significantly reduced from 19.55 at baseline to 12.4 at 24 weeks and 11.8 at 48 weeks (p < 0.001)17.
Safety
The adverse event profile of infliximab in this indication is expected to be in line with that described in the summary of product characteristics (SmPC)1. Upper respiratory tract infection was the most common adverse drug reaction (ADR) reported in clinical trials, occurring in 25.3% of infliximab-treated patients compared with 16.5% of control patients. The most serious ADRs associated with the use of tumour necrosis factor blockers that have been reported for infliximab include hepatitis B virus reactivation, congestive heart failure, serious infections (including sepsis, opportunistic infections and tuberculosis), serum sickness (delayed hypersensitivity reactions), haematologic reactions, systemic lupus erythematosus or lupus-like syndrome and serious infusion reactions1.
The very common (≥ 1 in 10) side effects reported from infliximab infusion across all indications for use include: viral infections (such as influenza, herpes virus infection), headache, upper respiratory tract infection, sinusitis, and abdominal pain, nausea, infusion-related reaction and pain1.
The recommended baseline monitoring for infliximab is complete metabolic profile, complete blood count with differential, tuberculosis test, serologic tests for hepatitis B and C, and HIV test for higher risk patients18. Ongoing monitoring needed is an annual tuberculosis test and liver function tests at three months after starting treatment then every 6 to 12 months afterwards18.
In the randomised controlled trial of infliximab, no unexpected adverse events were reported during the study14. Likewise, in the meta-analysis by Shih et al. (2022) the most common adverse events were in line with the expected side effect profile for infliximab15.
In the study by Srour et al. (2026) adverse events were noted in 22.5% of patients, most were mild and included muscle pain, transient elevated liver enzymes and infections requiring antibiotic treatment17.
Acquacalda et al. (2015) and Van Rappard et al. (2011) both report cases of polyarthritis following treatment with infliximab for HS19,20. Acquacalda et al. noted three of 11 patients with severe, therapy-resistant HS developed an acute and painful polyarthritis, without systemic reaction, during infliximab infusion leading to the discontinuation of treatment19. In two of the cases polyarthritis developed soon after the 4th and 8th infliximab infusion and resolved 12 weeks after discontinuation in both. In the third case, polyarthritis developed two months after the 16th infusion infliximab and resolved after four months. In the three cases no rheumatological flare was reported 24, 26 and 12 months later19.
In a retrospective study, van Rappard et al. reported five of 27 patients (18%) developed an acute and painful polyarthritis during treatment with infliximab for HS20. On average, the arthritis started after 12 months of treatment; it was not clearly associated with anti-infliximab antibodies and resolved in an average of four months. No patients had a history of arthritis and all showed a good skin response to infliximab. Arthritis was not observed in any of the control groups studied (227 patients with HS not treated with any biologic, 22 patients with HS treated with adalimumab, and 28 patients with psoriasis treated with infliximab). Compared with the adalimumab group the odds ratio of developing arthritis was calculated to be 7.241 (95% CI: 1.15 to 45.6), and compared with the psoriasis group, the odds ratio was 9.025 (95% CI: 1.45 to 55.82)20.
Discussion
The highest quality evidence for efficacy is a single RCT of infliximab versus placebo in 38 patients with moderate-to-severe HS, conducted in 2010. No new clinical trials of infliximab in this indication have been conducted that compare infliximab with other biologics or placebo. The severity of HS was defined using an HSSI score which captures inflammatory burden, whilst Hurley staging focusses on the degree of scarring. Moderate and severe HS as defined by HSSI may not align with moderate to severe Hurley staging. At the time the RCT was conducted, no biologics were licensed to treat HS and infliximab was administered as a first-line biologic treatment. Limited data is available for later line use, in the retrospective cohort study by Le et al. (2026), prior treatment with adalimumab did not appear to significantly affect response to infliximab.
The RCT had a treatment period of eight weeks, with an observation period of a further 44 weeks. There are no data for longer-term treatment. Although the primary end point of a ≥ 50% decrease from baseline in HSSI after eight weeks was higher in the infliximab group than in the placebo group, the difference was not statistically significant. Post-hoc analyses showed a significant difference between the two groups for achieving a 25% to 50% decrease in HSSI from baseline with infliximab. The use of infliximab is recommended by the European Hidradenitis Suppurativa Foundation’s guideline, predominantly based on the results of the RCT13. The guideline also recommends continued maintenance treatment beyond the initial eight-week treatment period that was included in the study, stating that evidence for long-term use (one year) is only based on a single-centre case series of eight patients with moderate-to-severe HS13.
Clinicians in Wales note that no licensed biologics to treat HS have demonstrated long-term treatment success. Therefore, they have requested the assessment of infliximab to provide another option for patients in Wales for whose HS does not respond to, or has stopped responding to, licensed biologics; and also for patients for whom the licensed treatments are not suitable.
For patients who have an inadequate response to 5 mg/kg infliximab every eight weeks, clinicians have requested that the frequency of dose can be increased to up to every four weeks. The rationale provided is that in the marketing authorisation for secukinumab for treatment of HS there is the option to increase dose frequency from every four weeks to every two weeks based on clinical response. There is one study described where patients were initiated on four-weekly dosing regimen following failure of adalimumab treatment. The study reported an improvement in HS symptoms and quality of life at this dose17. Five of the ten studies included in the systematic review by Shih et al. (2022) included either increased dose of infliximab (up to 10 mg/kg) or increased frequency of dose (up to every four weeks). The findings were not stratified by regimen though infliximab was found to have an overall beneficial effect in treating moderate to severe HS.
Clinicians indicate that even if new biologics become available for HS in Wales, because of the chronic nature of HS and the relatively short drug survival times of biologics to treat it, there is still likely to be a place for infliximab in HS therapy.
The safety profile of infliximab has been established and in the majority of HS studies no new adverse effects were reported. The study by Srour et al. (2026) demonstrated that an increase in frequency to four weekly was well tolerated and adverse events were mild and manageable17. Two studies report that polyarthritis might be an unwanted effect that seems to occur in a small number of HS patients treated with infliximab19,20. It may be prudent to monitor and advise patients of this rare adverse event which typically occurs after 12 months of treatment and resolves on treatment discontinuation.
No cost-effectiveness evidence was identified for this use of infliximab, no cost-effectiveness analyses have been undertaken.
The cost of infliximab is provided in Table 1 and is based on the weighted average of NHS Wales contract prices for the reference product and biosimilars with 2024 secondary care prescribing data. The standard dose of infliximab is 5 mg/kg on Weeks 0, 2 and 6 and every 8 weeks thereafter. Clinical experts estimate that in 30% of cases, HS will not respond or the treatment will not be tolerated and will be discontinued after the initial three doses of infliximab, assuming that a response has not been seen by Week 12. This 30% discontinuation rate has also been applied to the comparators.
Infliximab is to be reserved for patients whose HS has failed to respond or who have contraindications to treatment with licensed and approved biologic therapies. Active comparator treatments would be either bimekizumab or off-label upadacitinib accessed through IPFR. These would also be the only treatment options for patients whose HS does not respond to treatment with adalimumab or secukinumab, or for whom these treatments are unsuitable. Where these options are unavailable or unsuitable, patients will receive best supportive care (BSC), which may include continued treatment with topical or oral antibiotics, dapsone, retinoids, ciclosporin and antiandrogens. Treatments offered are tailored to the individual and courses of treatment may be cycled. Therefore, there is no standard BSC. Costs for BSC have been estimated based on the treatments included for the NICE TA935 appraisal of secukinumab, and durations of treatment from the European guidelines for HS treatment6,13. An average of all treatments was calculated to provide an estimate of the annual cost of BSC. The annual costs for comparators are provided in Table 2.
Bimekizumab is administered as a subcutaneous injection; the SmPC states that after proper training, patients may self-inject if their physician determines that it is appropriate21. Upadacitinib is an oral tablet, therefore there are no associated administration costs. The dose (15 mg or 30 mg) is based on individual patient presentation22.
Clinicians estimate that 10 patients will receive infliximab per year. Each patient will receive treatment for up to two years. For simplicity the comparator biologics have been split 50:50 and the discontinuation rate rounded up or down to equate to the same number of patients as infliximab remaining on active treatment. The alternative scenario is BSC and all patients are assumed to remain on this treatment throughout the two years. Table 3 provides an estimate of the net annual cost of treating HS with infliximab as an alternative to bimekizumab or upadacitinib or BSC. The budget impact estimates that infliximab would incur savings of [commercial in confidence text removed] in Year 1 and [commercial in confidence text removed] in Year 2. Compared to BSC alone, infliximab would incur an additional cost of [commercial in confidence text removed] in Year 1 and [commercial in confidence text removed] in Year 2. Clinicians have requested consideration of an increase in dose frequency to 5 mg/kg infliximab up to every 4 weeks for patients who have an inadequate response. It is estimated that approximately half of all responders will require an increase in frequency after six months of the standard regimen. Costs and scenario analyses for increased frequency are provided in Tables 4 and 5. The estimated associated budget impact savings are [commercial in confidence text removed] in Year 1 and [commercial in confidence text removed] in Year 2. The cost incurred compared with BSC would be [commercial in confidence text removed] in Year 1 and [commercial in confidence text removed] in Year 2.
Table 1. Estimated annual cost of infliximab in Wales (per patient) (opens image in new tab)
Table 2. Estimated annual cost of comparators in Wales (per patient) (opens image in new tab)
Table 3. Estimated budget impact in Wales, standard dosing infliximab (opens image in new tab)
Table 4. Estimated annual cost of infliximab every 4 weeks in Wales (per patient) (opens image in new tab)
Table 5. Estimated budget impact in Wales, scenario analysis with dose frequency increased to every four weeks after six months treatment (opens image in new tab)
Budget impact issues
Garg et al. (2020) conducted a multinational survey of patients with HS during October 2017 to July 201826. The Global Survey of Impact and Healthcare Needs (Global VOICE) project aimed to evaluate the unmet needs of patients with HS. Patients identified several critical unmet needs, including: delays in getting a formal diagnosis of HS (mean delay 10.2 ± 8.9 years); experiencing disease flare (daily flare reported by 23% of patients; weekly flare by 29.8% and monthly flare by 31.1%); HS-related pain (rated by 61.4% as moderate pain or higher, with 4.5% describing pain over the past week to be the worst possible); visiting the emergency department (18.3%) or being hospitalised (12.5%) five times or more for symptoms; and 43.3% (n = 563) reported an extreme impact on life, with 14.5% reporting they were disabled due to disease and unable to work. Patients also reported a high frequency of comorbidities, most commonly anxiety and depression. Many patients were dissatisfied with medical treatment (45.9%) or procedural treatments (34.6%) most commonly because of perceived poor efficacy and undesirable adverse effects. The level of optimism for having satisfactory control of symptoms within the next three months was low or very low in 45.9% of participants26.
Results of the RCT showed significant improvements from baseline (p < 0.005) in DLQI scores in the infliximab group, with patients achieving more than 50% improvement compared with the placebo group14.
Questionnaires submitted to AWTTC by HS patients echo the above findings with particular reference to extreme pain, toll on mental health, impact on relationships and restrictions to everyday activities. Patients welcome any new treatment which may reduce flares and, in particular, the pain associated with this condition.
AWTTC have completed an Equality and Health Impact Assessment in parallel with each development stage of the project. This follows the five ways of working for public bodies, and work to achieving the wellbeing goals, outlined in the Well‑Being of Future Generations (Wales) Act 2015.
It is not expected that infliximab will have significant potential negative impact on people based on the protected characteristics of the Equality Act 2010.
Prescribing unlicensed medicines
Infliximab is not licensed to treat this indication and is therefore prescribed ‘off label’. Prescribers should consult their relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.
Care has been taken to ensure the information is accurate and complete at the time of publication. However, the All Wales Therapeutics and Toxicology Centre (AWTTC) do not make any guarantees to that effect. The information in this document is subject to review and may be updated or withdrawn at any time. AWTTC accept no liability in association with the use of its content.
Information presented in this document can be reproduced using the following citation: All Wales Therapeutics & Toxicology Centre. Evidence Status Report. Infliximab to treat moderate to severe hidradenitis suppurativa that does not respond to licensed treatments or when licensed treatments are not suitable. Reference number: OW37. 2026.
Copyright AWTTC 2026. All rights reserved.
1. Janssen-Cilag Ltd. Remicade®. 100 mg powder for concentrate for solution for infusion. Summary of Product Characteristics. Jul 2025. Available at: https://www.medicines.org.uk/emc/product/3831/smpc. Accessed Sep 2026.
2. National Health Service. Hidradenitis suppurativa. Mar 2023. Available at: https://www.nhs.uk/conditions/hidradenitis-suppurativa/. Accessed Sep 2026.
3. Living Life With HS. What is HS? Information about hidradenitis suppurativa (HS). 2026. Available at: https://livinglifewithhs.co.uk/what-is-hs/. Accessed Sep 2026.
4. Ingram JR, Collier F, Brown D et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. British Journal of Dermatology. 2019;180:pp1009–1017.
5. National Institute for Health and Care Excellence. Technology Appraisal TA392. Adalimumab for treating moderate to severe hidradenitis suppurativa. Jun 2016. Available at: https://www.nice.org.uk/guidance/ta392. Accessed Aug 2026.
6. National Institute for Health and Care Excellence. Technology Appraisal TA935. Secukinumab for treating moderate to severe hidradenitis suppurativa. Dec 2023. Available at: https://www.nice.org.uk/guidance/ta935. Accessed Aug 2026.
7. Prens LM, Bouwman K, Aarts P et al. Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study. British Journal of Dermatology. 2021;185:177–184.
8. Ring HC, Thorsen J, Kirby B et al. Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study. British Journal of Dermatology. 2024;190(5):769–771.
9. British Skin Foundation. Hidradenitis suppurativa. 2026. Available at: https://www.britishskinfoundation.org.uk/conditions/hidradenitis-suppurativa. Accessed Sep 2026.
10. National Institute for Health and Care Excellence. Technology Appraisal TA1028. Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal). Jan 2025. Available at: https://www.nice.org.uk/guidance/ta1028. Accessed Sep 2026.
11. National Institute for Health and Care Excellence. ID6666. GID-TA11825. Upadacitinib for treating moderate to severe hidradenitis suppurativa in people 12 years and over. Sep 2025. Available at: https://www.nice.org.uk/guidance/awaiting-development/gid-ta11825. Accessed Sep 2026.
12. National Institute for Health and Care Excellence. ID6569. GID-TA11743. Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor. Apr 2025. Available at: https://www.nice.org.uk/guidance/indevelopment/gid-ta11743. Accessed Sep 2026.
13. Zouboulis CC, Bechara FG, Behadou F et al. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: treatment. Journal of the European Academy of Dermatology and Venereology. 2025;39:899–941.
14. Grant A, Gonzalez T, Montgomery MO et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. Journal of the American Academy of Dermatology. 2010;62(2):205–217.
15. Shih T, Lee K, Grogan T et al. Infliximab in hidradenitis suppurativa: a systematic review and meta-analysis. Dermatologic Therapy. 2022;35(9):e15691.
16. Le DV, Tran HT, Shrestha R et al. Therapeutic infliximab levels are associated with improved clinical outcomes in hidradenitis suppurativa: a pilot retrospective cohort study. Journal of the American Academy of Dermatology. 2026.
17. Srour R, Shapiro J, Avitan-Hersh E et al. From Failure to Success: Evaluating Infliximab Efficacy After Adalimumab Failure in Hidradenitis Suppurativa. Dermatologic Therapy. 2026;9020978.
18. Holcomb ZE, Porter ML, and Kimball AB. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs. Expert Opinion on Drug Safety. 2021;20(10):1147–1161.
19. Acquacalda E, Roux CH, Albert C et al. New onset of articular inflammatory manifestations in patients with hidradenitis suppurativa under treatment with infliximab. Joint Bone Spine. 2015;82:362–364.
20. van Rappard DC, Mooij JE, Baeten DLP et al. New-onset polyarthritis during successful treatment of hidradenitis suppurativa with infliximab. British Journal of Dermatology. 2011;165:194–198.
21. UCB Pharma Limited. Bimzelx®. 160 mg solution for injection in pre-filled pen. Summary of Product Characteristics. Apr 2026. Available at: https://www.medicines.org.uk/emc/product/12834/smpc. Accessed Sep 2026.
22. AbbVie Ltd. RINVOQ®.15 mg prolonged-release tablets. Summary of Product Characteristics. Jun 2026. Available at: https://www.medicines.org.uk/emc/product/10972/smpc. Accessed Sep 2026.
23. NHS England. National Cost Collection Data Publication: National Schedule 2024/25. Nov 2025. Available at: https://www.england.nhs.uk/publication/2024-25-national-cost-collection-data-publication/. Accessed Sep 2026.
24. Haymarket Publications. Monthly Index of Medical Specialities (MIMS). Sep 2026. Available at: http://www.mims.co.uk/. Accessed Sep 2026.
25. Oliveira M, Rahawi K, Duan Y et al. Effect of biologics on the need for procedural interventions, systemic medications, and healthcare utilization in patients with hidradenitis suppurativa: real-world data from the UNITE registry. Dermatology and Therapy. 2023;13:1577–1585.
26. Garg A, Neuren E, Cha D et al. Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. Journal of the American Academy of Dermatology. 2020;82(2):366–376.
Medicine details |
|
| Medicine name | infliximab |
| One Wales decision status | Supported for use via the One Wales Medicines process |
| Reference number | OW37 |
| Decision issue date | November 2026 |
| Review schedule | After 12 months |